Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders

Blood Pressure

Volumn 17, Issue SUPPL. 2, 2008, Pages 31-40

  Nickenig, Georg ^a   Simanenkov, Vladimir ^b   Lembo, Giuseppe ^c   Rodriguez, Pablo ^d   Salko, Thomas ^e   Ritter, Shannon ^e   Zhang, Jack ^e  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b City Oncology Hospital   (Russian Federation)

^c IRCCS NEUROMED   (Italy)

^d Hypertension Unit ^*  (Argentina)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Direct renin inhibitor; Hypertension; Non responder; Single pill combination

Indexed keywords

ALISKIREN; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; CREATININE; NITROGEN; POTASSIUM; UREA; AMIDE; DIURETIC AGENT; FUMARIC ACID DERIVATIVE; HYDROCHLOROTHIAZIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NEUROLOGIC DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; ADOLESCENT; BIOASSAY; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TIME FACTORS; ADOLESCENT; DIURETICS; DRUG RESISTANCE; ENDPOINT DETERMINATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649448321     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020802507290     Document Type: Article

References (22)

1. Frampton, J. E. and Curran, M. P. (2007) Aliskiren: A review of its use in the management of hypertension. Drugs, 67, pp. 1767-1792.
2. Oh, B. H., Mitchell, J., Herron, J. R., Chung, J., Khan, M. and Keefe, D. L. (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol, 49, pp. 1157-1163.
3. Palatini, P., Jung, W., Shlyakhto, E., Botha, J., Bheda, M. and Keefe, D. L. (2008) Blood pressure reduction following a simulated missed dose of aliskiren, irbesartan, or ramipril: A comparative ambulatory blood pressure monitoring study. J Clin Hypertens, 10, pp. A31-2-P-62.
4. Weir, M. R., Bush, C., Anderson, D. R., Zhang, J., Keefe, D. L. and Satlin, A. (2007) Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens, 1, pp. 264-277.
5. Vaidyanathan, S., Jarugula, V., Dieterich, H-A., Howard, D. and Dole, W. P. (2008) Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet, 47, pp. 515-531.
6. Zhao, C., Vaidyanathan, S., Yeh, C-M., Maboudian, M. and Dieterich, H-A. (2006) Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes. Clin Pharmacokinet, 45, pp. 1125-1134.
7. O'Brien, E., Barton, J., Nussberger, J., Mulcahy, D., Jensen, C. Dicker, P. et al. (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 49, pp. 276-284.
8. Villamil, A., Chrysant, S. G., Calhoun, D., Schober, B., Hsu, H. Matrisciano-Dimichino, L. et al. (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens, 25, pp. 217-226.
9. Sica, D., Gradman, A. H., Lederballe, O., Meyers, M., Cai, J. and Keefe, D. L. (2006) Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J, 27, p. 121 P.
10. Gradman, A. H., Kolloch, R., Meyers, M., Cai, J. and Zhang, J. (2007) Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension. J Clin Hypertens, 9, p. A160 P.
11. Strasser, R. H., Puig, J. G., Farsang, C., Croket, M., Li, J. and van Ingen, H. (2007) A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens, 21, pp. 780-787.
12. Andersen, K., Weinberger, M. H., Egan, B., Constance, C. M., Ali, M. A. Jin, J. et al. (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens, 26, pp. 589-599.
13. Bangalore, S., Kamalakkannan, G., Parkar, S. and Messerli, F. H. (2007) Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med, 120, pp. 713-719.
14. Williams, B., Poulter, N. R., Brown, M. J., Davis, M., McInnes, G. T. Potter, J. F. et al. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ, 328, pp. 634-640.
15. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr, J. L. et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, pp. 1206-1252.
16. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R. Germano, G. et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25, pp. 1105-1187.
17. Blumenstein, M., Romaszko, J., Calderon, A., Andersen, K., Zhang, J. Ibram, G. et al. (2008) Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCTZ) fixed-dose combination tablets in patients with hypertension who are not adequately responsive to HCTZ. J Clin Hypertens, 10, p. A12 P.
18. Law, M. R., Wald, N. J., Morris, J. K. and Jordan, R. E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ, 326, pp. 1427-1434.
19. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, pp. 1903-1913.
20. Jordan, J., Engeli, S., Boye, S. W., Breton, S. Le and Keefe, D. L. (2007) Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension, 49, pp. 1047-1055.
21. Zillich, A. J., Garg, J., Basu, S., Bakris, G. L. and Carter, B. L. (2006) Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension, 48, pp. 219-224.
22. NCEP ATP III (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, pp. 2486-2497.